Clinical

Dataset Information

HMBD-001 in Advanced HER3 Positive Solid Tumours


ABSTRACT: This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in patients with advanced HER3 positive solid tumours. The main aims are to find out the maximum dose of HMBD-001 that can be given safely to patients alone and in combination with other anti-cancer agents, more about the potential side effects of HMBD-001 and how these can be treated and what happens to HMBD-001 inside the body and how it affects cancer cells.

DISEASE(S): Endometrial Cancer,Cervical Cancer,Triple Negative Breast Neoplasms,Hepatocellular Carcinoma (hcc),Melanoma,Bladder Cancer,Triple Negative Breast Cancer,Head And Neck Neoplasms,Pancreatic Cancer,Endometrial Neoplasms,Non-small Cell Lung Cancer (nsclc),Ras Wild Type Colorectal Cancer,Neoplasms, Squamous Cell,Ovarian Cancer,Carcinoma, Squamous Cell,Oesophageal Cancer,Gastric Cancer,Squamous Cell Cancer Of The Head And Neck,Castration-resistant Prostate Cancer

PROVIDER: 2390619 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR